摘要
目的探讨多西紫杉醇在晚期非小细胞肺癌(NSCLC)化疗中的应用效果。方法选取2016年1~12月我院收治的40例晚期NSCLC患者,按照患者的住院单双号将其分成对照组和实验组,每组各20例。对照组采用紫杉醇+顺铂同步化疗,实验组采用多西紫杉醇联合顺铂同步化疗。比较两组的客观有效率、近期疗效、不良反应发生情况及随访1、2年的生存率。结果实验组与对照组的客观有效率分别为35.00%、25.00%,差异无统计学意义(P>0.05)。随访后发现实验组的1及2年生存率均明显高于对照组,差异有统计学意义(P<0.05)。实验组与对照组的不良反应总发生率分别为25.00%、30.00%,差异无统计学意义(P>0.05)。结论在晚期NSCLC的常规化疗中采用多西紫杉醇治疗,可有效提高患者的生存率,降低死亡率,其远期疗效较为理想,且不良反应较少,值得临床借鉴和推广应用。
Objective To investigate the effect of Docetaxel in the chemotherapy of advanced non-small cell lung cancer(NSCLC).Methods Forty patients with advanced NSCLC treated in Xiangyaping Collaborative Hospital from January and December 2016 were selected.They were divided into the control group and the experimental group according to odd or even number of hospital admission,20 cases in each group.In the control group,Paclitaxel+Cisplatin for simultaneous chemotherapy were used,and in the experimental group,Docetaxel+Cisplatin for simultaneous chemotherapy were adopted.The objective effectiveness rate,short-term effect,adverse reactions,and survival rates within 1 and 2 years of follow-up were compared between the two groups.Results The objective effectiveness rates of the experimental group and the control group were 35.00%and 25.00%,respectively,the difference had no statistical significance(P>0.05).After follow-up,the 1 and 2 year survival rates of the experimental group were significantly higher than those of the control group with statistical differences(P<0.05).The total incidence of adverse reactions in the experimental group and the control group were 25.00%and 30.00%,the difference had no statistical significance(P>0.05).Conclusion The use of Docetaxel in the conventional chemotherapy for advanced NSCLC can effectively increase the survival rate and reduce the mortality with a favorable long-term efficacy and few adverse reactions,which is worthy of clinical reference and promotion.
作者
花小梅
彭辉
王江涛
文兆明
肖仁斌
吴娟
HUA Xiao-mei;PENG Hui;WANG Jiang-tao;WEN Zhao-ming;XIAO Ren-bin;WU Juan(Department of Oncology,Xiangyaping Collaborative Hospital,Jiangxi Province,Pingxiang 337000,China;Department of Basic,Jiangxi Vocational College of Health,Pingxiang 337000,China)
出处
《中国当代医药》
2019年第23期53-55,共3页
China Modern Medicine
关键词
多西紫杉醇
晚期
非小细胞肺癌
化疗
不良反应
Docetaxel
Advanced
Non-small cell lung cancer
Chemotherapy
Adverse reactions
